Clinical characteristics | TNBC grouping (N = 251) | OR | 95% CI | P | |
---|---|---|---|---|---|
HER2neg | HER2low | ||||
n = 94 (37.5%) | n = 157 (62.5%) | ||||
Age (years) |  |  | 1.97 | 1.09–3.57 | 0.03 |
 < 45 | 29 (30.9) | 29 (18.5) |  |  |  |
 ≥ 45 | 65 (69.1) | 128 (81.5) |  |  |  |
Menstrual status |  |  | 0.68 | 0.39–1.17 | 0.17 |
 Pre | 59 (62.8%) | 112 (71.3%) |  |  |  |
 Post | 35 (37.2%) | 45 (28.7%) |  |  |  |
Lesion |  |  | 0.95 | 0.57–1.58 | 0.90 |
 Left | 46 (48.9%) | 79 (50.3%) |  |  |  |
 Others | 48 (51.1%) | 78 (49.7%) |  |  |  |
NST |  |  | 0.91 | 0.54–1.51 | 0.80 |
 No | 48 (51.1%) | 84 (53.5%) |  |  |  |
 Yes | 46 (48.9%) | 73 (46.5%) |  |  |  |
Tumor size |  |  | 1.93 | 1.04–3.57 | 0.04 |
 < 2 cm | 26 (27.7%) | 26 (16.6%) |  |  |  |
 ≥ 2 cm | 68 (72.3%) | 131 (83.4%) |  |  |  |
Lymph node metastasis |  |  | 1.85 | 1.10–3.13 | 0.02 |
 Negative | 45 (47.9%) | 52 (33.1%) |  |  |  |
 Positive | 49 (52.1%) | 105 (66.9%) |  |  |  |
Distant metastasis |  |  | 0.85 | 0.31–2.30 | 0.8 |
 Negative | 87 (92.6%) | 147 (93.6%) |  |  |  |
 Positive | 7 (7.4%) | 10 (6.4%) |  |  |  |
Pathological type |  |  | 1.53 | 0.85–2.77 | 0.16 |
 Ductal | 73 (77.7%) | 109 (69.4%) |  |  |  |
 Others | 21 (22.3%) | 48 (35.5%) |  |  |  |
Ki67, % |  |  | 5.97 | 3.16–11.31 | < 0.001 |
 < 30 | 41 (43.6%) | 18 (11.5%) |  |  |  |
 ≥ 30 | 53 (56.4%) | 139 (88.5%) |  |  |  |
Histological grade |  |  | 2.68 | 1.41–5.12 | < 0.01 |
 I/II | 79 (84.0%) | 104 (66.2%) |  |  |  |
 III | 15 (16.0%) | 53 (33.8%) |  |  |  |